Universe Pharmaceuticals INC
UPC
$4.91
-$0.21-4.10%
NASDAQ
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 0.00% | -21.30% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.00% | -21.30% | |||
| Cost of Revenue | 0.00% | -21.83% | |||
| Gross Profit | 0.00% | -19.79% | |||
| SG&A Expenses | 0.00% | 19.68% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 0.00% | 212.28% | |||
| Total Operating Expenses | 0.00% | 12.28% | |||
| Operating Income | 0.00% | -260.87% | |||
| Income Before Tax | 0.00% | 134.70% | |||
| Income Tax Expenses | 0.00% | -108.78% | |||
| Earnings from Continuing Operations | 0.00% | 133.39% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.00% | 133.39% | |||
| EBIT | 0.00% | -260.87% | |||
| EBITDA | 0.00% | -305.23% | |||
| EPS Basic | 0.00% | -- | |||
| Normalized Basic EPS | 0.00% | -- | |||
| EPS Diluted | 0.00% | -- | |||
| Normalized Diluted EPS | 0.00% | -- | |||
| Average Basic Shares Outstanding | 0.00% | -- | |||
| Average Diluted Shares Outstanding | 0.00% | -- | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||